Review
Cladribine (2-chloro-2'-deoxyadenosine): new perspectives in clinical immunosuppression
Affiliations
- PMID: 7503626
Item in Clipboard
Review
Cladribine (2-chloro-2'-deoxyadenosine): new perspectives in clinical immunosuppression
Arch Immunol Ther Exp (Warsz).
1994.
Abstract
Cladribine (2-chloro-2'-deoxyadenosine) has been recently introduced in the treatment of hematologic malignancies. We have shown that CdA has potent inhibitory activity in vitro and in vivo in concentrations readily achievable in the sera of treated patients. The immunosuppressive efficacy of CdA was at least equal to that of cyclosporine. Furthermore, CdA is particularly efficacious inhibitor of B cell activation.
Similar articles
-
Discovery, mechanism and expected clinical significance of selective cytotoxicity of 2-chloro-2'-deoxyadenosine (2-CdA).Arch Immunol Ther Exp (Warsz). 1994;42(1):1-5. Arch Immunol Ther Exp (Warsz). 1994. PMID: 7503624 Review.
-
Cladribine (2-chloro-deoxyadenosine, CDA): an inhibitor of human B and T cell activation in vitro.Immunopharmacology. 1993 Nov-Dec;26(3):197-202. doi: 10.1016/0162-3109(93)90035-o. Immunopharmacology. 1993. PMID: 7904595
-
2-Chloro-2-deoxyadenosine--a novel immunosuppressive agent.Transplantation. 1993 Nov;56(5):1253-7. Transplantation. 1993. PMID: 7902627 No abstract available.
-
2-Chlorodeoxyadenosine: lack of synergism with cyclosporine A and tacrolimus (FK 506).Arch Immunol Ther Exp (Warsz). 1995;43(5-6):329-32. Arch Immunol Ther Exp (Warsz). 1995. PMID: 8744655
-
A pilot study of 2-chloro-2'-deoxyadenosine in the treatment of systemic lupus erythematosus-associated glomerulonephritis.Arthritis Rheum. 1998 Feb;41(2):335-43. doi: 10.1002/1529-0131(199802)41:2<335::AID-ART18>3.0.CO;2-O. Arthritis Rheum. 1998. PMID: 9485092 Review.
Cited by
-
Apoptosis by 2-chloro-2'-deoxy-adenosine and 2-chloro-adenosine in human peripheral blood mononuclear cells.Neurochem Int. 1998 May-Jun;32(5-6):493-504. doi: 10.1016/s0197-0186(97)00129-0. Neurochem Int. 1998. PMID: 9676749 Free PMC article.